西格列汀联合贝那普利治疗糖尿病肾病的临床观察

发布时间：2018-06-23 20:59

本文选题：西格列汀 + 贝那普利　；参考：《中国药房》2017年05期

【摘要】：目的:观察西格列汀联合贝那普利治疗糖尿病肾病(DN)的临床效果。方法:将我院2014年9月-2015年6月收治的60例DN患者按随机数字表法分为西格列汀组、贝那普利组和联合用药组,各20例。在常规治疗基础上,西格列汀组患者口服西格列汀100 mg,qd;贝那普利组患者口服贝那普利10 mg,qd;联合用药组患者口服西格列汀100 mg+贝那普利10 mg,qd。患者血压若未达标,则将用药剂量加倍;疗程均为12周。测定3组患者治疗前后的24h尿蛋白、白细胞介素6(IL-6)和血清胱抑素C(CysC)水平,观察临床疗效和不良反应发生情况。结果:联合用药组患者的总有效率(90.00%)显著高于西格列汀组(65.00%)和贝那普利组(70.00%),差异有统计学意义(P0.05)。治疗后,3组患者的24 h尿蛋白、IL-6和CysC水平均较治疗前显著降低,且联合用药组显著低于两单独用药组,差异均有统计学意义(P0.05)。西格列汀组和贝那普利组的上述指标比较,差异均无统计学意义(P0.05)。3组患者在治疗期间均未见明显不良反应发生。结论:西格列汀和贝那普利均能降低DN患者的24 h尿蛋白、IL-6和CysC水平,但联合用药的效果更显著,并具有更高的临床有效率,且不影响用药安全性。
[Abstract]:Objective: to observe the clinical effect of siglitatin combined with benazepril in the treatment of diabetic nephropathy (DN). Methods: from September 2014 to June 2015, 60 patients with DN were randomly divided into three groups: ciglutin group, benazepril group and combined therapy group (20 cases each). On the basis of routine therapy, the patients in the siglitatin group were orally administered with 100 mg of ciglutin QD, the patients in the benazepril group were given 10 mg of benazepril QD, and the patients in the combined treatment group were given 100 mg benazepril 10 mg / g QD. If the blood pressure was not up to the standard, the dosage was doubled, and the course of treatment was 12 weeks. The levels of urinary protein, interleukin-6 (IL-6) and serum cystatin C (CysC) were measured before and after treatment, and the clinical efficacy and adverse reactions were observed. Results: the total effective rate of combined treatment group (90.00%) was significantly higher than that of siglitatin group (65.00%) and benazepril group (70.00%). The difference was statistically significant (P0.05). After treatment, the levels of IL-6 and CysC in 24 h urine protein in three groups were significantly lower than those before treatment, and the levels of IL-6 and CysC in combination group were significantly lower than those in two groups alone (P0.05). There was no significant difference in the above indexes between the ciglutin group and benazepril group (P0.05). Conclusion: both siglitatin and benazepril can decrease the levels of IL-6 and CysC in 24 h urine of DN patients, but the combined therapy is more effective and has a higher clinical effective rate, and does not affect the safety of drug use.
【作者单位】：芜湖市第二人民医院内分泌科;芜湖市第二人民医院心内科;
【分类号】：R587.2

【相似文献】